Related Experiment Videos
The Tertatolol International Multicenter Study (T.I.M.S.). Predicting factors of an efficient therapy
E Agnes1, C Vandermercken, J F Prost
1Institut de Recherches Internationales Servier, Neuilly-sur-Seine, France.
American Journal of Hypertension
|November 1, 1989
Summary
This study found that 5 mg of tertatolol daily effectively controlled hypertension in most patients. Younger patients with lower initial diastolic blood pressure and higher heart rate were more likely to succeed with single-drug therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Mild to moderate hypertension requires effective and tolerable treatment options.
- Identifying predictors for successful monotherapy can optimize hypertension management.
Purpose of the Study:
- To assess the efficacy and tolerability of 5 mg tertatolol daily for one year.
- To identify clinical predictors for successful single beta-blocker therapy in hypertension.
Main Methods:
- A multicenter study involving 230 patients with mild to moderate hypertension.
- A one-year open-label period following placebo and double-blind phases.
- Diuretics were added for inadequately controlled blood pressure.
Main Results:
- 88.5% of patients achieved controlled blood pressure (≤90 mm Hg diastolic) after one year.
- 56.3% were controlled on tertatolol alone, while 32.2% required dual therapy (tertatolol + diuretic).
- Predictors for successful monotherapy included lower initial standing diastolic BP, higher standing heart rate, younger age, and lower sitting systolic BP.
Conclusions:
- Tertatolol demonstrates significant antihypertensive efficacy and tolerability.
- Specific baseline clinical parameters can predict successful single beta-blocker therapy, aiding clinical decision-making.